Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dr. Reddy's
Biotech
Dr. Reddy's pens $370M pact for rights to Immutep's LAG-3 agent
The deal notably doesn’t give the Indian generics giant the rights to eftilagimod in the key markets of North America, Europe, China and Japan.
James Waldron
Dec 8, 2025 10:55am
Coya taps familiar friend Dr. Reddy's to commercialize ALS med
Dec 6, 2023 11:20am
Chutes & Ladders—Gilead cancer clinical chief jumps to Compugen
Mar 30, 2018 8:15am
Encore's first pipeline play is psoriasis drug from Dr. Reddy's
Aug 22, 2017 10:32am
